Announcing all-new research partnership
Powered by COS
We are thrilled to announce the launch of Oncology Outcomes: Strategic Advisory Partnership – a collaborative partnership with Alicyn Campbell.
“This partnership sees us dramatically expanding the scope of our oncology resources and expertise available to our clients. Through this world-class research group, we will be bringing a patient-centered focus to oncology drug development and real-world evidence generation through strategic advising.”
Stacie Hudgens, COS’s Chief Executive Officer
Pictured left to right, Stacie Hudgens, Tara Symonds and Alicyn Campbell.
To provide dedicated strategic advice for your oncology patient-centered evidence strategy.
Through this oncology advisory partnership, we will support you on every step of the journey: from early development to post-approval, including real world surveillance.
Our combined qualitative, quantitative, and regulatory expertise will demonstrate the value (or clinical benefit) of your product to key stakeholders (e.g. patients, providers, regulators, and reimbursement authorities).
COS has worked extensively in oncology since its start in 2013 to incorporate qualitative inquiry and advance quantitative methods in cancer research. Stacie Hudgens has worked in the oncology COA space for the past 20 years in her industry, academic, and consultancy roles. She has extensive publications and presentations detailing novel methodologies for analyzing and interpreting COA endpoints in clinical trials. Alongside Tara Symonds, Louise Newton, and Claire Burbridge, she has co-led the development of real-world research methods to triangulate evidence from multiple stakeholder groups. Stacie has participated in a number of oncology-specific working groups and continues to work to push the scientific standards for understanding treatment burden for cancer patients.
Joining forces with COS is Alicyn Campbell. Alicyn is widely regarded for her expertise and leadership in the assessment of the patient experience in oncology. She has over 12 years of experience developing and implementing patient relevant endpoint strategies across all areas of oncology. Most recently, Alicyn led Roche/Genentech’s oncology patient-centered outcomes research group, in which capacity she was responsible for novel FDA PRO labeling claims for both Hycela and Hemlibra. Alicyn is a sought-after speaker and thought leader, having been invited to participate in numerous FDA workshops, public forums, and initiatives, including Former Vice President Biden’s Cancer Moonshot Initiative.
Speak to: Stacie Hudgens
Stacie Hudgens, Chief Executive Officer Strategic Lead, Regulatory & Access can be reached at our United States Office (Tucson):
1820 E. River Rd, Suite 220 Tucson 85718
Phone (+1) 520-325-9510
Clinical Outcomes Solutions are proud to partner with Patient Relevant Evidence.